![people idea icon - Opthea](https://opthea.com/wp-content/uploads/2023/01/people-idea-icon.png)
Our Vision
Advancing bold therapeutic innovation and inspiring transformation in the global retinal community.
![mission icon - Opthea](https://opthea.com/wp-content/uploads/2023/01/mission-icon.png)
Our Mission
Dedicated to improving and protecting vision in people with retinal diseases.
Company Overview
Opthea Limited (NASDAQ: OPT, ASX: OPT) is a global biopharmaceutical company aspiring to become the leader of therapeutic innovation in retinal diseases.
We started with a vision of the future, where the impact of retinal disease is reduced, and patients’ quality-of-life is enhanced. With people as our focus, we assembled a world-class team of ophthalmology experts in pursuit of breakthrough therapies. Together we focused on scientific innovation for those who suffer from retinal disease. Today, we are translating our discoveries into promising new medicines.
![Company Overview Scientists - Opthea Company Overview Scientists](https://opthea.com/wp-content/uploads/2023/04/company-overview-scientists@2x.png)
Management Team
Our executive leadership team has the experience, determination, and resources to make a positive and significant impact on the retinal community. We are building a culture of success that drives our transformation and leadership role as an important global ally in retinal care. Click the links below to learn more about the people who are leading our patient-focused mission.
Fred Guerard • PharmD, MS
Chief Executive Officer
Peter Lang • MBA
Chief Financial Officer
Megan Baldwin • PhD, MAICD
Founder, Chief Innovation Officer and Executive Director
Judith Robertson • MBA
Chief Commercial Officer
Julie Clark • MD
Senior Vice President of Clinical Development
Fang Li • PhD
Senior Vice President Regulatory Affairs
Bruno Gagnon • BPharm, MSc
Senior Vice President, Global Clinical Operations
Karen Adams • B.BBUS, CPA, GAICD, FCC GFIA
Vice President Finance and Company Secretary
Mark O’Neill
Vice President CMC
John Han • PharmD
Vice President, Medical Affairs
Mike Gerometta • PhD
Head of CMC Development
Sarika Gulhar • PhD
Executive Director of Human Resources
Ian Leitch • PhD
Director of Clinical Research
Board of Directors
Our board believes in the promising future of our company and in the power of our transformational science and technology to establish a new standard-of-care for retinal diseases. Our board members bring the strategic expertise and necessary skills needed to help the company succeed, and collectively they provide important oversight and governance of the business.
Medical Advisory Board (MAB)
The members of the MAB advise the Company on opportunities to address the still unmet medical needs of patients with retinal diseases and help guide our development efforts.
Arshad M. Khanani • MD, MA, FASRS
Chief Medical Advisor
Chair, Opthea Medical Advisory Board
David S. Boyer • MD
Andrew Chang • AM, MBBS (Hons), PhD FRANZCO, FRACS
Frank G. Holz • MD, FEBO, FARVO
Anat Loewenstein • MD, MHA
Dante Pieramici • MD
Carl Regillo • MD, FASRS
Patricio G. Schlottmann • MD
Eric Souied • MD, PhD
Tien Y Wong • MD, PhD
Clinical Advisory Board (CAB)
The members of the CAB provide independent expert advice on the Company’s clinical development programs.
![company-tim-jackson@2x - Opthea Tim Jackson](https://opthea.com/wp-content/uploads/2023/02/company-tim-jackson@2x.jpg)
Tim Jackson
PhD, MB, ChB, FRCOphth • National Health Service Consultant Ophthalmic Surgeon at King’s College Hospital, London
![Jason Slakter - Opthea Jason Slakter](https://opthea.com/wp-content/uploads/2023/02/company-jason-slakter@2x.jpg)
Jason Slakter
MD • Clinical Professor of Ophthalmology at New York University School of Medicine, and partner at Vitreous Retina Macula Consultants Of New York
![company-charles-wykoff@2x - Opthea](https://opthea.com/wp-content/uploads/2022/12/company-charles-wykoff@2x.jpg)
Charles C. Wykoff
MD, PhD • Director of Research, Retina Consultants of Texas; Chairman of Research and Clinical Trials Committee, Retina Consultants of America; Deputy Chair for Opthalmology, Blanton Eye Institute, Houston Methodist Hospital